<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE Publisher PUBLIC "-//Springer-Verlag//DTD A++ V2.4//EN" "http://devel.springer.de/A++/V2.4/DTD/A++V2.4.dtd">
<Publisher>
  <PublisherInfo>
    <PublisherName>Springer New York</PublisherName>
    <PublisherLocation>New York, NY</PublisherLocation>
    <PublisherImprintName>Springer</PublisherImprintName>
  </PublisherInfo>
  <Book Language="En">
    <BookInfo BookProductType="Contributed volume" ContainsESM="No" Language="En" MediaType="eBook" NumberingStyle="ChapterOnly" OutputMedium="All" TocLevels="0">
      <BookID>978-1-60327-829-4</BookID>
      <BookTitle>Drug Management of Prostate Cancer</BookTitle>
      <BookDOI>10.1007/978-1-60327-829-4</BookDOI>
      <BookTitleID>158057</BookTitleID>
      <BookPrintISBN>978-1-60327-831-7</BookPrintISBN>
      <BookElectronicISBN>978-1-60327-829-4</BookElectronicISBN>
      <BookChapterCount>37</BookChapterCount>
      <BookCopyright>
        <CopyrightHolderName>Springer Science+Business Media, LLC</CopyrightHolderName>
        <CopyrightYear>2010</CopyrightYear>
      </BookCopyright>
      <BookSubjectGroup>
        <BookSubject Code="SCH" Type="Primary">Medicine &amp; Public Health</BookSubject>
        <BookSubject Code="SCH33160" Priority="1" Type="Secondary">Oncology</BookSubject>
        <BookSubject Code="SCH62002" Priority="2" Type="Secondary">Urology</BookSubject>
        <BookSubject Code="SCH33002" Priority="3" Type="Secondary">Internal Medicine</BookSubject>
        <SubjectCollection Code="SUCO11650">Medicine</SubjectCollection>
      </BookSubjectGroup>
    </BookInfo>
    <BookHeader>
      <EditorGroup>
        <Editor AffiliationIDS="AffID1">
          <EditorName DisplayOrder="Western">
            <GivenName>William D.</GivenName>
            <FamilyName>Figg</FamilyName>
          </EditorName>
          <Contact>
            <Phone>301402-3622</Phone>
            <Fax>301402-8606</Fax>
            <Email>wdfigg@helix.nih.gov</Email>
          </Contact>
        </Editor>
        <Editor AffiliationIDS="AffID2">
          <EditorName DisplayOrder="Western">
            <GivenName>Cindy H.</GivenName>
            <FamilyName>Chau</FamilyName>
          </EditorName>
          <Contact>
            <Email>chauc@mail.nih.gov</Email>
          </Contact>
        </Editor>
        <Editor AffiliationIDS="AffID3">
          <EditorName DisplayOrder="Western">
            <GivenName>Eric J.</GivenName>
            <FamilyName>Small</FamilyName>
          </EditorName>
          <Contact>
            <Phone>415/353-7171</Phone>
            <Email>smalle@medicine.ucsf.edu</Email>
          </Contact>
        </Editor>
        <Affiliation ID="AffID1">
          <OrgDivision>Medical Oncology Branch</OrgDivision>
          <OrgName>NIH National Cancer Institute</OrgName>
          <OrgAddress>
            <Street>Rockville Pike 9000</Street>
            <City>Bethesda</City>
            <Postcode>20892</Postcode>
            <State>Maryland</State>
            <Country>USA</Country>
          </OrgAddress>
        </Affiliation>
        <Affiliation ID="AffID2">
          <OrgDivision>Medical Oncology Branch</OrgDivision>
          <OrgName>NIH National Cancer Institute</OrgName>
          <OrgAddress>
            <Street>Rockville Pike 9000</Street>
            <City>Bethesda</City>
            <Postcode>20892</Postcode>
            <State>Maryland</State>
            <Country>USA</Country>
          </OrgAddress>
        </Affiliation>
        <Affiliation ID="AffID3">
          <OrgDivision>School of Medicine, Dept. Urology</OrgDivision>
          <OrgName>University of California, San Francisco</OrgName>
          <OrgAddress>
            <Street>Divisadero Street 1600</Street>
            <City>San Francisco</City>
            <Postcode>94115</Postcode>
            <State>California</State>
            <Country>USA</Country>
          </OrgAddress>
        </Affiliation>
      </EditorGroup>
    </BookHeader>
    <Part ID="Part2">
      <PartInfo OutputMedium="All" TocLevels="0">
        <PartID>2</PartID>
        <PartNumber>Part I</PartNumber>
        <PartSequenceNumber>2</PartSequenceNumber>
        <PartTitle>Hormone Therapy</PartTitle>
        <PartChapterCount>9</PartChapterCount>
        <PartContext>
          <BookID>978-1-60327-829-4</BookID>
          <BookTitle>Drug Management of Prostate Cancer</BookTitle>
        </PartContext>
      </PartInfo>
      <Chapter ID="Chap4" Language="En">
        <ChapterInfo ChapterType="OriginalPaper" ContainsESM="No" Language="En" NumberingStyle="ChapterOnly" OutputMedium="All" TocLevels="0">
          <ChapterID>4</ChapterID>
          <ChapterNumber>Chapter 4</ChapterNumber>
          <ChapterDOI>10.1007/978-1-60327-829-4_4</ChapterDOI>
          <ChapterSequenceNumber>4</ChapterSequenceNumber>
          <ChapterTitle Language="En">Androgens and Prostate Cancer</ChapterTitle>
          <ChapterFirstPage>53</ChapterFirstPage>
          <ChapterLastPage>59</ChapterLastPage>
          <ChapterCopyright>
            <CopyrightHolderName>Springer Science+Business Media, LLC</CopyrightHolderName>
            <CopyrightYear>2010</CopyrightYear>
          </ChapterCopyright>
          <ChapterHistory>
            <RegistrationDate>
              <Year>2010</Year>
              <Month>4</Month>
              <Day>16</Day>
            </RegistrationDate>
            <OnlineDate>
              <Year>2010</Year>
              <Month>8</Month>
              <Day>3</Day>
            </OnlineDate>
          </ChapterHistory>
          <ChapterGrants Type="Regular">
            <MetadataGrant Grant="OpenAccess"/>
            <AbstractGrant Grant="OpenAccess"/>
            <BodyPDFGrant Grant="Restricted"/>
            <BodyHTMLGrant Grant="Restricted"/>
            <BibliographyGrant Grant="Restricted"/>
            <ESMGrant Grant="Restricted"/>
          </ChapterGrants>
          <ChapterContext>
            <PartID>2</PartID>
            <BookID>978-1-60327-829-4</BookID>
            <BookTitle>Drug Management of Prostate Cancer</BookTitle>
          </ChapterContext>
        </ChapterInfo>
        <ChapterHeader>
          <AuthorGroup>
            <Author AffiliationIDS="Aff1_4" CorrespondingAffiliationID="Aff1_4">
              <AuthorName DisplayOrder="Western">
                <GivenName>Douglas</GivenName>
                <GivenName>K.</GivenName>
                <FamilyName>Price</FamilyName>
              </AuthorName>
              <Contact>
                <Email>dkprice@mai.nih.gov</Email>
              </Contact>
            </Author>
            <Author>
              <AuthorName DisplayOrder="Western">
                <GivenName>Ann</GivenName>
                <GivenName>W.</GivenName>
                <FamilyName>Hsing</FamilyName>
              </AuthorName>
            </Author>
            <Affiliation ID="Aff1_4">
              <OrgDivision>Medical Oncology Branch, National Cancer Institute</OrgDivision>
              <OrgName>National Institutes of Health</OrgName>
              <OrgAddress>
                <City>Bethesda</City>
                <State>MD</State>
                <Country>USA</Country>
              </OrgAddress>
            </Affiliation>
          </AuthorGroup>
          <Abstract ID="Abs1_4" Language="En" OutputMedium="All">
            <Heading>Abstract</Heading>
            <Para TextBreak="No">Prostate cancer is the most common nonskin cancer among American men and the third leading cause of cancer deaths. Research data over many years of study support the role of androgen in driving prostate cancer growth, proliferation, and progression. Androgens are steroid hormones that induce the differentiation and maturation of the male reproductive organs. Testosterone is the principal androgen in circulation, while dihydrotestosterone (DHT) is the primary nuclear androgen, and the action of DHT in the prostate is mediated by the androgen receptor. Within the prostate, DHT binds to the androgen receptor to form an intracellular complex that binds to androgen-response elements in the DNA of prostate cells inducing proliferation. Testosterone deficiency is common among aging American males, and a number of men suffering from testosterone deficiency may be relieved of their symptoms, receiving a boost in their quality of life, but are often denied treatment due to the fear that the addition of higher testosterone from replacement therapy may cause growth of occult prostate cancer. Several small studies show that, with the right patient population, testosterone replacement after curative therapy is safe. However, a large placebo-controlled prospective trial to provide the definitive study is needed.</Para>
          </Abstract>
          <KeywordGroup Language="En" OutputMedium="All">
            <Heading>Keywords</Heading>
            <Keyword>Prostate cancer</Keyword>
            <Keyword>Androgens</Keyword>
            <Keyword>Testosterone</Keyword>
            <Keyword>Replacement therapy</Keyword>
          </KeywordGroup>
        </ChapterHeader>
        <Body>
          <Section1 ID="Sec1" Type="Introduction">
            <Heading>Introduction</Heading>
            <Para TextBreak="No">Prostate cancer is the most common nonskin cancer among American men and the third leading cause of cancer deaths, behind lung and colorectal cancer [<CitationRef CitationID="CR1_4">1</CitationRef>]. Despite its high morbidity and mortality, few risk factors have been established other than age, race, and family history [<CitationRef CitationID="CR2_4">2</CitationRef>]. Recently, several genome-wide association studies (GWAS) have identified a number of genomic regions, including several in 8q24, that have been consistently linked to prostate cancer risk in several populations [<CitationRef CitationID="CR3_4">3</CitationRef>–<CitationRef CitationID="CR9_4">9</CitationRef>], although the function of the variants are unclear. Both clinical and laboratory data suggest that androgens play a pivotal role in prostate growth, maintenance, and carcinogenesis [<CitationRef CitationID="CR10_4">10</CitationRef>, <CitationRef CitationID="CR11_4">11</CitationRef>]. However, data from serum-based epidemiologic studies in human are inconclusive [<CitationRef CitationID="CR12_4">12</CitationRef>–<CitationRef CitationID="CR14_4">14</CitationRef>].</Para>
          </Section1>
          <Section1 ID="Sec2">
            <Heading>Androgen and the Prostate</Heading>
            <Section2 ID="Sec3">
              <Heading>Biosynthesis and Metabolism of Androgens</Heading>
              <Para TextBreak="No">Androgens are steroid hormones that induce the differentiation and maturation of the male reproductive organs and the development of male secondary sex characteristics. In men, androgens are formed primarily in the testes and the adrenal gland, and to a lesser extent in peripheral tissues, such as the prostate and skin. Biosynthesis of androgens in the endocrine glands occurs by well-characterized biosynthetic pathways as shown in Fig. <InternalRef RefID="Fig1">4.1</InternalRef>.<Figure Category="Standard" Float="Yes" ID="Fig1">
                  <Caption Language="En">
                    <CaptionNumber>Fig. 4.1</CaptionNumber>
                    <CaptionContent>
                      <SimplePara>Androgen metabolism pathways in the endocrine system. Androgen biosynthesis and metabolism within and outside the prostate gland</SimplePara>
                    </CaptionContent>
                  </Caption>
                  <MediaObject ID="MO1_4">
                    <ImageObject Color="BlackWhite" FileRef="MediaObjects/978-1-60327-829-4_4_Fig1_HTML.gif" Format="GIF" Rendition="HTML" Type="Linedraw"/>
                  </MediaObject>
                </Figure>
              </Para>
              <Para TextBreak="No">Testosterone (T) is the principal androgen in circulation, while dihydrotestosterone (DHT) is the primary nuclear androgen and the most potent androgen in tissue. In the circulation of adult males, roughly 44% of testosterone is bound with high affinity to sex hormone binding globulin (SHBG), 54% is bound with low affinity to albumin, and only 1–2% of testosterone exists in a free (unbound) state. About 25% of the DHT in the circulation is secreted by the testes while most (65–75%) arises from conversion of testosterone in peripheral tissue in a reaction catalyzed by the enzyme steroid 5α-reductase or from circulating inactive androgens, such as androstenedione, dehydroepiandrosterone (DHEA), and DHEA sulfate (DHEAS). In humans, two steroid 5α-reductase isoenzymes have been identified. The type 1 enzyme (encoded by the <Emphasis Type="Italic">SRD5A1</Emphasis> gene) is expressed mostly in skin and hair, whereas the type 2 enzyme (encoded by the <Emphasis Type="Italic">SRD5A2</Emphasis> gene) is localized primarily in androgen target tissue, including genital skin and the prostate [<CitationRef CitationID="CR15_4">15</CitationRef>].</Para>
              <Para TextBreak="No">In men, the prostate is a major site of nontesticular DHT production from testosterone. Free testosterone in circulation enters prostate cells by passive diffusion, whereas albumin-bound testosterone, because of its low affinity for albumin, can disassociate from albumin, allowing it to enter prostatic cells. Figure <InternalRef RefID="Fig2">4.2</InternalRef> shows the metabolic pathways of androgens within the prostate gland.<Figure Category="Standard" Float="Yes" ID="Fig2">
                  <Caption Language="En">
                    <CaptionNumber>Fig. 4.2</CaptionNumber>
                    <CaptionContent>
                      <SimplePara>Androgen action within the prostate cell</SimplePara>
                    </CaptionContent>
                  </Caption>
                  <MediaObject ID="MO2_4">
                    <ImageObject Color="BlackWhite" FileRef="MediaObjects/978-1-60327-829-4_4_Fig2_HTML.gif" Format="GIF" Rendition="HTML" Type="Linedraw"/>
                  </MediaObject>
                </Figure>
              </Para>
              <Para TextBreak="No">In androgen-sensitive tissue, including the prostate and skin, DHT (see Fig. <InternalRef RefID="Fig1">4.1</InternalRef>), the metabolite of T, is the most potent androgen. Intracellularly, T is irreversibly metabolized to DHT. DHT is then bound by an intracellular cytosolic receptor, the androgen receptor (AR). This complex is translocated to the cell nucleus, where it activates transcription of genes with hormone-responsive elements in their promoters and initiates a cascade of androgenic action. DHT can be inactivated in the prostate by further reduction to 3α- or 3β-androstanediol. DHT homeostasis is regulated by its (1) biosynthesis and (2) degradation (see Fig. <InternalRef RefID="Fig1">4.1</InternalRef>). Both processes involve multiple enzymatic steps, including the reactions catalyzed by the gene products of <Emphasis Type="Italic">CYP17A1</Emphasis>, <Emphasis Type="Italic">HSD17B3</Emphasis>, <Emphasis Type="Italic">HSD3B2, SRD5A2, CYP3A</Emphasis> genes, <Emphasis Type="Italic">UGT</Emphasis> genes, and <Emphasis Type="Italic">SULT</Emphasis> genes. Variation in these genes may be one endogenous source of variation in androgen action.</Para>
            </Section2>
          </Section1>
          <Section1 ID="Sec4">
            <Heading>Androgen Action on the Prostate</Heading>
            <Para TextBreak="No">The action of DHT in the prostate is mediated by the AR (see Fig. <InternalRef RefID="Fig2">4.2</InternalRef>). Within the prostate, DHT binds to the AR to form an intracellular complex, which binds to androgen-response elements in the DNA of prostate cells, ultimately inducing proliferation. Though the tissue concentration of DHT necessary to initiate the androgen cascade is unknown, just a minute amount is required to trigger androgenic action in prostate cancer patients who have undergone androgen ablation treatment, perhaps because such patients have hypersensitive ARs [<CitationRef CitationID="CR16_4">16</CitationRef>]. In the absence of androgen, nonandrogenic hormones including estradiol, vitamin D, and insulin-like growth factors (IGFs) can bind ARs, triggering androgenic action [<CitationRef CitationID="CR17_4">17</CitationRef>, <CitationRef CitationID="CR18_4">18</CitationRef>]. In addition, the activity of the AR is modulated by a series of coactivator proteins, including ARA54, ARA55, ARA70, ARA160, p160, BRCA1, AIB1, and CBP, which can enhance AR transcriptional activity several-fold [<CitationRef CitationID="CR9_4">9</CitationRef>–<CitationRef CitationID="CR21_4">21</CitationRef>]. Thus, androgenic action within the prostate is determined not only by androgen concentration but also by numerous other factors, including factors yet to be identified. However, no epidemiologic studies have directly assessed tissue hormone levels or androgenic action within the prostate, due in part to the difficulty in collecting prostate tissue from control subjects in case–control studies, or from men at baseline in cohort studies.</Para>
          </Section1>
          <Section1 ID="Sec5">
            <Heading>Androgen and Prostate Cancer</Heading>
            <Para TextBreak="No">Data from animal, clinical, and prevention studies support the role of androgen in prostate cancer growth, proliferation, and progression. However, serum-based epidemiologic studies in human have been inconclusive. Part of the inconsistency in these findings stems from differences in study population, assay accuracy, intraperson variation, and limited sample size. Recently, in a pooled analysis of 18 prospective studies, Roddam and the Endogenous Hormone and Prostate Cancer Collaborative Group reported no association between blood levels of total testosterone and prostate cancer risk based on data from 3,886 men with prostate cancer and 6,438 controls [<CitationRef CitationID="CR22_4">22</CitationRef>]. It is the largest serum-based study with the most elegant and comprehensive analysis to date to test a central hypothesis in prostate cancer etiology. It is not surprising that the pooled analysis did not find a positive link between circulating levels of total testosterone and prostate cancer risk since, individually, few of the 18 studies included in the pooled analysis reported a significant positive association.</Para>
            <Para TextBreak="No">Most recently, three prospective studies have each evaluated a large number (&gt;500) of cases in their nested case–control studies to clarify further the role of androgen in prostate cancer [<CitationRef CitationID="CR16_4">16</CitationRef>, <CitationRef CitationID="CR23_4">23</CitationRef>, <CitationRef CitationID="CR24_4">24</CitationRef>]. Overall, there is no convincing evidence of an association between serum androgens and total prostate cancer. However, there were suggestive associations between serum androgen and prostate cancer in certain disease subtypes. The Health Professional’s Follow-up study (460 case–control pairs) reported a suggestive association between total and free testosterone with an increased risk of low-grade disease [<CitationRef CitationID="CR23_4">23</CitationRef>]. The European Prospective Investigation into Cancer and Nutrition (EPIC) study (with 643 case-control pairs) found a significant inverse association of androstenedione concentration and risk for advanced prostate cancer, and weak positive associations between free testosterone concentration and risk for total prostate cancer among young men and risk for high-grade disease [<CitationRef CitationID="CR16_4">16</CitationRef>]. The Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial (the largest study to date with 727 incident Caucasian prostate cancer cases and 889 matched controls) found that a higher testosterone-to-SHBG ratio (T:SHBG) was related to increased risk primarily in men 65 years of age or older [<CitationRef CitationID="CR24_4">24</CitationRef>], but there was no association with total prostate cancer. None of the subtype findings appeared in more than one of these three studies.</Para>
            <Para TextBreak="No">Several reasons contribute to the mixed results from epidemiologic studies. First, serum androgen levels are indirect indicators of intraprostatic androgen levels and may not be an accurate reflection of androgen action within the prostate [<CitationRef CitationID="CR25_4">25</CitationRef>]. In addition, relatively large assay variation, intraperson variation, differences in study population, and heterogeneity of prostate cancer in these studies may contribute to the inability of epidemiologic studies to replicate results. Furthermore, genetic susceptibility in the androgen metabolic and signaling pathways may contribute to the effects that androgens have on prostate cancer. Therefore, future studies on the enigmatic relationship between androgens and prostate cancer should take these issues into account.</Para>
          </Section1>
          <Section1 ID="Sec6">
            <Heading>Testosterone Replacement Therapy and the Risk of Prostate Cancer</Heading>
            <Para TextBreak="No">Since the historic findings establishing prostate cancer’s dependence on androgens put forth by Huggins and Hodges in 1941, the interaction between testosterone and prostate cancer has been at the forefront of prostate cancer treatment. This Nobel Prize-winning initial work showed that prostate cancer regressed when serum testosterone (T) was reduced to castrate levels, and that an increase in T caused growth of prostate cancer [<CitationRef CitationID="CR10_4">10</CitationRef>]. Based on this discovery, surgical or chemical androgen blockade became the mainstay of hormonal treatment of prostate cancer.</Para>
            <Para TextBreak="No">Since this landmark discovery, the idea that higher serum T levels in patients cause an increase in prostate cancer growth has been ingrained in the minds of physicians and researchers, and it seems that this entrenched idea may have clouded a more important connection between low serum T and prostate cancer. The theory of increased T causing increased prostate cancer growth appears to be based on the idea that, because a reduction of T during castration causes regression of prostate cancer growth, then an increase in T should cause prostate cancer cells to grow. If this were true, the literature would be full of reports showing that testosterone replacement therapy (TRT) is associated with prostate cancer. However, a review of the present literature has failed to provide any evidence to support this theory. This belief in the unproven serum T “dogma” has, in turn, made TRT in hypogonadal men at risk for prostate cancer a rarely used treatment option.</Para>
            <Para TextBreak="No">Testosterone deficiency, also known as androgen deficiency of the aging male (ADAM), late-onset hypogonadism (LOH) and andropause, is common among aging American males, present in up to 39% of men between the ages of 45 and 85 [<CitationRef CitationID="CR26_4">26</CitationRef>]. This condition has been characterized by low serum testosterone, depression, a decrease in libido, lack of energy, decreased muscle mass, changes in bone mineral density, anemia, and cardiovascular risk factors (reviewed by Tostain and Blanc) [<CitationRef CitationID="CR27_4">27</CitationRef>]. A large number of men suffering from T deficiency who might be relieved of their symptoms and could also receive a boost in their quality of life are often denied treatment, if they are thought to be at risk to develop prostate cancer due to the fear that the addition of higher T from TRT may cause growth of occult prostate cancer. However, several reports have shown that there is no direct correlation between levels of T in serum, and the risk of developing prostate cancer [<CitationRef CitationID="CR28_4">28</CitationRef>, <CitationRef CitationID="CR29_4">29</CitationRef>], and that ethnicities with lower incidence of prostate cancer have higher serum T levels [<CitationRef CitationID="CR30_4">30</CitationRef>, <CitationRef CitationID="CR31_4">31</CitationRef>]. Actually, it has been shown that low, not high, levels of T are associated with prostate cancer [<CitationRef CitationID="CR26_4">26</CitationRef>, <CitationRef CitationID="CR32_4">32</CitationRef>–<CitationRef CitationID="CR34_4">34</CitationRef>], high Gleason grade cancer, advanced stage at initial presentation, and decreased survival [<CitationRef CitationID="CR35_4">35</CitationRef>–<CitationRef CitationID="CR38_4">38</CitationRef>]. Another argument against high levels of serum T and an association with prostate cancer can be made with the epidemiology of prostate cancer. Clinical diagnosis of carcinoma of the prostate is rare in young men (in their 20s and 30s) when serum T levels are at their highest but are much more common in aging men when serum T levels are much lower.</Para>
            <Para TextBreak="No">In the last 10 years, there have been many published reports investigating the treatment of hypogonadism in males using different formulations of testosterone, and for varying amounts of treatment and time of follow-up, and none of these studies has shown an increased risk of developing prostate cancer ([<CitationRef CitationID="CR39_4">39</CitationRef>–<CitationRef CitationID="CR43_4">43</CitationRef>], and reviewed by Rhoden and Morgentaler [<CitationRef CitationID="CR44_4">44</CitationRef>]). One example of these studies is the work done by Rhoden and Morgentaler in patients thought to be at high risk due to prostatic intraepithelial neoplasia (PIN). The authors reviewed charts of 75 men (20 with PIN and 55 without PIN), who presented with hypogonadal symptoms, and had a documented low serum T level. All 75 men reviewed had been on TRT for 1 year. Prostate cancer was diagnosed in only one man in the PIN arm, and none were diagnosed in the hypogonadal men without presence of PIN [<CitationRef CitationID="CR43_4">43</CitationRef>]. This 1% detection rate in the study group is similar to that found in screening trials [<CitationRef CitationID="CR44_4">44</CitationRef>, <CitationRef CitationID="CR45_4">45</CitationRef>]. In addition, PSA values have not been shown to increase significantly [<CitationRef CitationID="CR40_4">40</CitationRef>, <CitationRef CitationID="CR46_4">46</CitationRef>], nor has there been a change in concentration of DHT within the prostate following TRT [<CitationRef CitationID="CR47_4">47</CitationRef>].</Para>
          </Section1>
          <Section1 ID="Sec7">
            <Heading>Testosterone Replacement Therapy Following Treatment for Prostate Cancer</Heading>
            <Para TextBreak="No">While there have not been any large studies with long-term follow-up looking at the effects of TRT after primary treatment for prostate cancer, there has been several small studies. In the first study, Kaufman and Graydon identified seven men who had undergone a radical prostatectomy and had clinical symptoms of hypogonadism [<CitationRef CitationID="CR48_4">48</CitationRef>]. In all seven men, including four who had received T supplementation prior to prostate cancer diagnosis, all men had serum T levels in the eugonadal range prior to diagnosis, and were graded with Gleason 6 or 7 scores. At the time of publication, TRT had been shown to be safe, with no reported recurrences or metastases in a follow-up period that ranged from 1 to 12 years [<CitationRef CitationID="CR48_4">48</CitationRef>].</Para>
            <Para TextBreak="No">Agarwal and Oefelein also presented their findings of ten men, with clear symptoms of hypogonadism, who were treated with TRT following a radical prostatectomy for organ confined disease [<CitationRef CitationID="CR49_4">49</CitationRef>]. These ten men had no postoperative evidence of disease or rising PSA, but suffered from symptoms that included decreased libido, erectile dysfunction, and decreased quality of life. Upon determination of baseline PSA and serum T, all were started on T supplementation. The patients were routinely followed for both clinical and quality of life measurements. While all patients had the intended rise in serum T, none of these men had a detectable PSA. The median follow-up was 19 months and there was not a single recurrence observed. The authors noted that patients responded well to the increase in serum T with an increase in sexual function and overall energy level, and a reduction in hot flashes [<CitationRef CitationID="CR49_4">49</CitationRef>].</Para>
            <Para TextBreak="No">The third study evaluated TRT after brachytherapy for early prostate cancer [<CitationRef CitationID="CR50_4">50</CitationRef>]. In this study, Sarosdy retrospectively reviewed 31 patients who had undergone TRT for hypogonadism following brachytherapy for prostate cancer. The TRT was initiated from 0.5 to 4.5 (median 2.0 years) following radioactive seed implantation. These patients received TRT for 0.5–8.5 years (median 4.5 years) and were followed for 1.5–9.0 years (median 5.0 years). None of the 31 patients stopped TRT due to cancer recurrence or progression [<CitationRef CitationID="CR50_4">50</CitationRef>].</Para>
            <Para TextBreak="No">All authors of the above-mentioned studies agreed that while controversial, a history of prostate cancer should not absolutely preclude one from TRT as long as the patient has no detectable prostate cancer, and/or has had prior curative therapy. In all cases, the patients who are to receive TRT should be carefully selected, and should be at a low risk for recurrence. Hypogonadal candidates for TRT after therapy should only include those with minimal initial disease, possess low Gleason scores, and a negligible PSA. Monitoring of these patients should be more frequent, a PSA and total T determination every 1–3 months, at least for the first year has been suggested [<CitationRef CitationID="CR49_4">49</CitationRef>].</Para>
            <Para TextBreak="No">While the above studies showing positive results after radical prostatectomy and brachytherapy have been completed, no similar study has been done on patients who were treated with radiation alone. It has been suggested that TRT following radiation may not be a viable approach due to the residual prostatic tissue that remains following radiation therapy, which could be more susceptible to T supplementation [<CitationRef CitationID="CR49_4">49</CitationRef>]. These small studies together show that, with the right patient population that TRT after curative therapy is safe, and they show the need for a large placebo-controlled prospective trial to provide the definitive study.</Para>
          </Section1>
          <Section1 ID="Sec8" Type="Conclusion">
            <Heading>Conclusion</Heading>
            <Para TextBreak="No">While there is a large amount of evidence regarding the role of testosterone in the growth, proliferation, and progression of prostate cancer, more information is still needed. Mixed results in clinical studies have been inconsistent due to differences in the study population, accuracy issues in serum-based assays, sample size, and sample acquisition and storage. More uniform standards would enhance epidemiological studies in the future. Also, there is a great need for a definitive study investigating testosterone replacement, both to fully understand the risk of prostate cancer associated with this treatment, and recurrence after primary therapy for prostate cancer, in order to convince clinicians that TRT is a viable option for patients in need of testosterone replacement.</Para>
          </Section1>
        </Body>
        <BodyRef FileRef="BodyRef/PDF/978-1-60327-829-4_Chapter_4.pdf" OutputMedium="Online" PDFType="Typeset" TargetType="OnlinePDF"/>
        <ChapterBackmatter>
          <Acknowledgments>
            <Heading>Acknowledgment</Heading>
            <SimplePara>This work was supported by the Intramural Research Program of the NIH, National Cancer Institute.</SimplePara>
          </Acknowledgments>
          <Bibliography ID="Bib1">
            <Heading>References</Heading>
            <Citation ID="CR1_4">
              <CitationNumber>1.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>AW</Initials>
                  <FamilyName>Hsing</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AP</Initials>
                  <FamilyName>Chokkalingam</FamilyName>
                </BibAuthorName>
                <Year>2006</Year>
                <ArticleTitle Language="En">Prostate cancer epidemiology</ArticleTitle>
                <JournalTitle>Front Biosci</JournalTitle>
                <VolumeID>11</VolumeID>
                <FirstPage>1388</FirstPage>
                <LastPage>413</LastPage>
                <Occurrence Type="PID">
                  <Handle>16368524</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.2741/1891</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28XislSgu7Y%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Hsing AW, Chokkalingam AP. Prostate cancer epidemiology. Front Biosci 2006;11:1388–413.</BibUnstructured>
            </Citation>
            <Citation ID="CR2_4">
              <CitationNumber>2.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>AP</Initials>
                  <FamilyName>Chokkalingam</FamilyName>
                </BibAuthorName>
                <Year>2007</Year>
                <ArticleTitle Language="En">Molecular epidemiology of prostate cancer: hormone-related genetic loci</ArticleTitle>
                <JournalTitle>Front Biosci</JournalTitle>
                <VolumeID>12</VolumeID>
                <FirstPage>3436</FirstPage>
                <LastPage>60</LastPage>
                <Occurrence Type="PID">
                  <Handle>17485312</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.2741/2325</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXms1KmtL0%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Chokkalingam AP, et al. Molecular epidemiology of prostate cancer: hormone-related genetic loci. Front Biosci 2007;12:3436–60.</BibUnstructured>
            </Citation>
            <Citation ID="CR3_4">
              <CitationNumber>3.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>ML</Initials>
                  <FamilyName>Freedman</FamilyName>
                </BibAuthorName>
                <Year>2006</Year>
                <ArticleTitle Language="En">Admixture mapping identifies 8q24 as a prostate cancer risk locus in African-American men</ArticleTitle>
                <JournalTitle>Proc Natl Acad Sci U S A</JournalTitle>
                <VolumeID>103</VolumeID>
                <IssueID>38</IssueID>
                <FirstPage>14068</FirstPage>
                <LastPage>73</LastPage>
                <Occurrence Type="PID">
                  <Handle>16945910</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1073/pnas.0605832103</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28XhtVCmur7F</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Freedman ML, et al. Admixture mapping identifies 8q24 as a prostate cancer risk locus in African-American men. Proc Natl Acad Sci U S A 2006;103(38):14068–73.</BibUnstructured>
            </Citation>
            <Citation ID="CR4_4">
              <CitationNumber>4.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Gudmundsson</FamilyName>
                </BibAuthorName>
                <Year>2007</Year>
                <ArticleTitle Language="En">Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24</ArticleTitle>
                <JournalTitle>Nat Genet</JournalTitle>
                <VolumeID>39</VolumeID>
                <IssueID>5</IssueID>
                <FirstPage>631</FirstPage>
                <LastPage>7</LastPage>
                <Occurrence Type="PID">
                  <Handle>17401366</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1038/ng1999</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXksFersL0%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Gudmundsson J, et al. Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat Genet 2007;39(5):631–7.</BibUnstructured>
            </Citation>
            <Citation ID="CR5_4">
              <CitationNumber>5.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>CA</Initials>
                  <FamilyName>Haiman</FamilyName>
                </BibAuthorName>
                <Year>2007</Year>
                <ArticleTitle Language="En">Multiple regions within 8q24 independently affect risk for prostate cancer</ArticleTitle>
                <JournalTitle>Nat Genet</JournalTitle>
                <VolumeID>39</VolumeID>
                <IssueID>5</IssueID>
                <FirstPage>638</FirstPage>
                <LastPage>44</LastPage>
                <Occurrence Type="PID">
                  <Handle>17401364</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1038/ng2015</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXksFersLY%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Haiman CA, et al. Multiple regions within 8q24 independently affect risk for prostate cancer. Nat Genet 2007;39(5):638–44.</BibUnstructured>
            </Citation>
            <Citation ID="CR6_4">
              <CitationNumber>6.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Suuriniemi</FamilyName>
                </BibAuthorName>
                <Year>2007</Year>
                <ArticleTitle Language="En">Confirmation of a positive association between prostate cancer risk and a locus at chromosome 8q24</ArticleTitle>
                <JournalTitle>Cancer Epidemiol Biomarkers Prev</JournalTitle>
                <VolumeID>16</VolumeID>
                <IssueID>4</IssueID>
                <FirstPage>809</FirstPage>
                <LastPage>14</LastPage>
                <Occurrence Type="PID">
                  <Handle>17416775</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1158/1055-9965.EPI-06-1049</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXjvV2msrc%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Suuriniemi M, et al. Confirmation of a positive association between prostate cancer risk and a locus at chromosome 8q24. Cancer Epidemiol Biomarkers Prev 2007;16(4):809–14.</BibUnstructured>
            </Citation>
            <Citation ID="CR7_4">
              <CitationNumber>7.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JS</Initials>
                  <FamilyName>Witte</FamilyName>
                </BibAuthorName>
                <Year>2007</Year>
                <ArticleTitle Language="En">Multiple prostate cancer risk variants on 8q24</ArticleTitle>
                <JournalTitle>Nat Genet</JournalTitle>
                <VolumeID>39</VolumeID>
                <IssueID>5</IssueID>
                <FirstPage>579</FirstPage>
                <LastPage>80</LastPage>
                <Occurrence Type="PID">
                  <Handle>17460686</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1038/ng0507-579</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXksFers7o%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Witte JS. Multiple prostate cancer risk variants on 8q24. Nat Genet 2007;39(5):579–80.</BibUnstructured>
            </Citation>
            <Citation ID="CR8_4">
              <CitationNumber>8.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Yeager</FamilyName>
                </BibAuthorName>
                <Year>2007</Year>
                <ArticleTitle Language="En">Genome-wide association study of prostate cancer identifies a second risk locus at 8q24</ArticleTitle>
                <JournalTitle>Nat Genet</JournalTitle>
                <VolumeID>39</VolumeID>
                <IssueID>5</IssueID>
                <FirstPage>645</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>17401363</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1038/ng2022</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXksFersb4%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Yeager M, et al. Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet 2007;39(5):645–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR9_4">
              <CitationNumber>9.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>SL</Initials>
                  <FamilyName>Zheng</FamilyName>
                </BibAuthorName>
                <Year>2007</Year>
                <ArticleTitle Language="En">Association between two unlinked loci at 8q24 and prostate cancer risk among European Americans</ArticleTitle>
                <JournalTitle>J Natl Cancer Inst</JournalTitle>
                <VolumeID>99</VolumeID>
                <IssueID>20</IssueID>
                <FirstPage>1525</FirstPage>
                <LastPage>33</LastPage>
                <Occurrence Type="PID">
                  <Handle>17925536</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1093/jnci/djm169</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXhtlCqsbjF</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Zheng SL, et al. Association between two unlinked loci at 8q24 and prostate cancer risk among European Americans. J Natl Cancer Inst 2007;99(20):1525–33.</BibUnstructured>
            </Citation>
            <Citation ID="CR10_4">
              <CitationNumber>10.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Huggins</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CV</Initials>
                  <FamilyName>Hodges</FamilyName>
                </BibAuthorName>
                <Year>1941</Year>
                <ArticleTitle Language="En">The effects of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>1</VolumeID>
                <FirstPage>293</FirstPage>
                <LastPage>7</LastPage>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaH3MXkvVCrtw%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Huggins C, Hodges CV. The effects of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941;1:293–7.</BibUnstructured>
            </Citation>
            <Citation ID="CR11_4">
              <CitationNumber>11.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Sharifi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JL</Initials>
                  <FamilyName>Gulley</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WL</Initials>
                  <FamilyName>Dahut</FamilyName>
                </BibAuthorName>
                <Year>2005</Year>
                <ArticleTitle Language="En">Androgen deprivation therapy for prostate cancer</ArticleTitle>
                <JournalTitle>JAMA</JournalTitle>
                <VolumeID>294</VolumeID>
                <IssueID>2</IssueID>
                <FirstPage>238</FirstPage>
                <LastPage>44</LastPage>
                <Occurrence Type="PID">
                  <Handle>16014598</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1001/jama.294.2.238</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXmtlSlt7g%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA 2005;294(2):238–44.</BibUnstructured>
            </Citation>
            <Citation ID="CR12_4">
              <CitationNumber>12.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>LW</Initials>
                  <FamilyName>Chu</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JK</Initials>
                  <FamilyName>Reichardt</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AW</Initials>
                  <FamilyName>Hsing</FamilyName>
                </BibAuthorName>
                <Year>2008</Year>
                <ArticleTitle Language="En">Androgens and the molecular epidemiology of prostate cancer</ArticleTitle>
                <JournalTitle>Curr Opin Endocrinol Diabetes Obes</JournalTitle>
                <VolumeID>15</VolumeID>
                <IssueID>3</IssueID>
                <FirstPage>261</FirstPage>
                <LastPage>70</LastPage>
                <Occurrence Type="PID">
                  <Handle>18438175</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1097/MED.0b013e3282febcf6</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXlvFantbg%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Chu LW, Reichardt JK, Hsing AW. Androgens and the molecular epidemiology of prostate cancer. Curr Opin Endocrinol Diabetes Obes 2008;15(3):261–70.</BibUnstructured>
            </Citation>
            <Citation ID="CR13_4">
              <CitationNumber>13.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>AW</Initials>
                  <FamilyName>Hsing</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JK</Initials>
                  <FamilyName>Reichardt</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>FZ</Initials>
                  <FamilyName>Stanczyk</FamilyName>
                </BibAuthorName>
                <Year>2002</Year>
                <ArticleTitle Language="En">Hormones and prostate cancer: current perspectives and future directions</ArticleTitle>
                <JournalTitle>Prostate</JournalTitle>
                <VolumeID>52</VolumeID>
                <IssueID>3</IssueID>
                <FirstPage>213</FirstPage>
                <LastPage>35</LastPage>
                <Occurrence Type="PID">
                  <Handle>12111697</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/pros.10108</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38XmsVWqtbk%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Hsing AW, Reichardt JK, Stanczyk FZ. Hormones and prostate cancer: current perspectives and future directions. Prostate 2002;52(3):213–35.</BibUnstructured>
            </Citation>
            <Citation ID="CR14_4">
              <CitationNumber>14.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>EA</Initials>
                  <FamilyName>Platz</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Giovannucci</FamilyName>
                </BibAuthorName>
                <Year>2004</Year>
                <ArticleTitle Language="En">The epidemiology of sex steroid hormones and their signaling and metabolic pathways in the etiology of prostate cancer</ArticleTitle>
                <JournalTitle>J Steroid Biochem Mol Biol</JournalTitle>
                <VolumeID>92</VolumeID>
                <IssueID>4</IssueID>
                <FirstPage>237</FirstPage>
                <LastPage>53</LastPage>
                <Occurrence Type="PID">
                  <Handle>15663987</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/j.jsbmb.2004.10.002</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXkvVSitw%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Platz EA, Giovannucci E. The epidemiology of sex steroid hormones and their signaling and metabolic pathways in the etiology of prostate cancer. J Steroid Biochem Mol Biol 2004;92(4):237–53.</BibUnstructured>
            </Citation>
            <Citation ID="CR15_4">
              <CitationNumber>15.</CitationNumber>
              <BibChapter>
                <BibAuthorName>
                  <Initials>FZ</Initials>
                  <FamilyName>Stanczyk</FamilyName>
                </BibAuthorName>
                <Year>1996</Year>
                <ChapterTitle Language="En">Alterations in circulating levels of androgens and PSA during treatment with Fiansteride in men at high risk for prostate cancer</ChapterTitle>
                <BibEditorName>
                  <Initials>JJ</Initials>
                  <FamilyName>Li</FamilyName>
                </BibEditorName>
                <Eds/>
                <BookTitle>Hormonal carcinogenesis II</BookTitle>
                <PublisherName>Springer</PublisherName>
                <PublisherLocation>New York</PublisherLocation>
              </BibChapter>
              <BibUnstructured>Stanczyk FZ, et al. Alterations in circulating levels of androgens and PSA during treatment with Fiansteride in men at high risk for prostate cancer. In: Li JJ, et al., editors. Hormonal carcinogenesis II. New York: Springer; 1996.</BibUnstructured>
            </Citation>
            <Citation ID="CR16_4">
              <CitationNumber>16.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>RC</Initials>
                  <FamilyName>Travis</FamilyName>
                </BibAuthorName>
                <Year>2007</Year>
                <ArticleTitle Language="En">Serum androgens and prostate cancer among 643 cases and 643 controls in the European prospective investigation into cancer and nutrition</ArticleTitle>
                <JournalTitle>Int J Cancer</JournalTitle>
                <VolumeID>121</VolumeID>
                <IssueID>6</IssueID>
                <FirstPage>1331</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>17514649</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/ijc.22814</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXhtVSmtL%2FO</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Travis RC, et al. Serum androgens and prostate cancer among 643 cases and 643 controls in the European prospective investigation into cancer and nutrition. Int J Cancer 2007;121(6):1331–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR17_4">
              <CitationNumber>17.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>NL</Initials>
                  <FamilyName>Chamberlain</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>ED</Initials>
                  <FamilyName>Driver</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RL</Initials>
                  <FamilyName>Miesfeld</FamilyName>
                </BibAuthorName>
                <Year>1994</Year>
                <ArticleTitle Language="En">The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function</ArticleTitle>
                <JournalTitle>Nucleic Acids Res</JournalTitle>
                <VolumeID>22</VolumeID>
                <IssueID>15</IssueID>
                <FirstPage>3181</FirstPage>
                <LastPage>6</LastPage>
                <Occurrence Type="PID">
                  <Handle>8065934</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1093/nar/22.15.3181</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2cXlvFOns7o%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Chamberlain NL, Driver ED, Miesfeld RL. The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucleic Acids Res 1994;22(15):3181–6.</BibUnstructured>
            </Citation>
            <Citation ID="CR18_4">
              <CitationNumber>18.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Richter</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Srivastava</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Dobi</FamilyName>
                </BibAuthorName>
                <Year>2007</Year>
                <ArticleTitle Language="En">Androgen receptor and prostate cancer</ArticleTitle>
                <JournalTitle>Prostate Cancer Prostatic Dis</JournalTitle>
                <VolumeID>10</VolumeID>
                <IssueID>2</IssueID>
                <FirstPage>114</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>17297502</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1038/sj.pcan.4500936</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXlvFalu7s%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Richter E, Srivastava S, Dobi A. Androgen receptor and prostate cancer. Prostate Cancer Prostatic Dis 2007;10(2):114–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR19_4">
              <CitationNumber>19.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>Z</Initials>
                  <FamilyName>Culig</FamilyName>
                </BibAuthorName>
                <Year>1997</Year>
                <ArticleTitle Language="En">Hyperactive androgen receptor in prostate cancer: what does it mean for new therapy concepts?</ArticleTitle>
                <JournalTitle>Histol Histopathol</JournalTitle>
                <VolumeID>12</VolumeID>
                <IssueID>3</IssueID>
                <FirstPage>781</FirstPage>
                <LastPage>6</LastPage>
                <Occurrence Type="PID">
                  <Handle>9225161</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2sXls1Wltrw%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Culig Z, et al. Hyperactive androgen receptor in prostate cancer: what does it mean for new therapy concepts? Histol Histopathol 1997;12(3):781–6.</BibUnstructured>
            </Citation>
            <Citation ID="CR20_4">
              <CitationNumber>20.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>AW</Initials>
                  <FamilyName>Hsing</FamilyName>
                </BibAuthorName>
                <Year>2002</Year>
                <ArticleTitle Language="En">Polymorphic CAG/CAA repeat length in the AIB1/SRC-3 gene and prostate cancer risk: a population-based case-control study</ArticleTitle>
                <JournalTitle>Cancer Epidemiol Biomarkers Prev</JournalTitle>
                <VolumeID>11</VolumeID>
                <IssueID>4</IssueID>
                <FirstPage>337</FirstPage>
                <LastPage>41</LastPage>
                <Occurrence Type="PID">
                  <Handle>11927493</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38XjtlCmtr0%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Hsing AW, et al. Polymorphic CAG/CAA repeat length in the AIB1/SRC-3 gene and prostate cancer risk: a population-based case-control study. Cancer Epidemiol Biomarkers Prev 2002;11(4):337–41.</BibUnstructured>
            </Citation>
            <Citation ID="CR21_4">
              <CitationNumber>21.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Rahman</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Miyamoto</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Chang</FamilyName>
                </BibAuthorName>
                <Year>2004</Year>
                <ArticleTitle Language="En">Androgen receptor coregulators in prostate cancer: mechanisms and clinical implications</ArticleTitle>
                <JournalTitle>Clin Cancer Res</JournalTitle>
                <VolumeID>10</VolumeID>
                <IssueID>7</IssueID>
                <FirstPage>2208</FirstPage>
                <LastPage>19</LastPage>
                <Occurrence Type="PID">
                  <Handle>15073094</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1158/1078-0432.CCR-0746-3</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXivFSru7k%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Rahman M, Miyamoto H, Chang C. Androgen receptor coregulators in prostate cancer: mechanisms and clinical implications. Clin Cancer Res 2004;10(7):2208–19.</BibUnstructured>
            </Citation>
            <Citation ID="CR22_4">
              <CitationNumber>22.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>AW</Initials>
                  <FamilyName>Roddam</FamilyName>
                </BibAuthorName>
                <Year>2008</Year>
                <ArticleTitle Language="En">Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies</ArticleTitle>
                <JournalTitle>J Natl Cancer Inst</JournalTitle>
                <VolumeID>100</VolumeID>
                <IssueID>3</IssueID>
                <FirstPage>170</FirstPage>
                <LastPage>83</LastPage>
                <Occurrence Type="PID">
                  <Handle>18230794</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1093/jnci/djm323</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXivFygsrg%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Roddam AW, et al. Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J Natl Cancer Inst 2008;100(3):170–83.</BibUnstructured>
            </Citation>
            <Citation ID="CR23_4">
              <CitationNumber>23.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>EA</Initials>
                  <FamilyName>Platz</FamilyName>
                </BibAuthorName>
                <Year>2005</Year>
                <ArticleTitle Language="En">Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the prostate-specific antigen era</ArticleTitle>
                <JournalTitle>Cancer Epidemiol Biomarkers Prev</JournalTitle>
                <VolumeID>14</VolumeID>
                <IssueID>5</IssueID>
                <FirstPage>1262</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>15894683</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1158/1055-9965.EPI-04-0371</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXktFCkt7k%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Platz EA, et al. Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the prostate-specific antigen era. Cancer Epidemiol Biomarkers Prev 2005;14(5):1262–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR24_4">
              <CitationNumber>24.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JM</Initials>
                  <FamilyName>Weiss</FamilyName>
                </BibAuthorName>
                <Year>2008</Year>
                <ArticleTitle Language="En">Endogenous sex hormones and the risk of prostate cancer: a prospective study</ArticleTitle>
                <JournalTitle>Int J Cancer</JournalTitle>
                <VolumeID>122</VolumeID>
                <IssueID>10</IssueID>
                <FirstPage>2345</FirstPage>
                <LastPage>50</LastPage>
                <Occurrence Type="PID">
                  <Handle>18172860</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/ijc.23326</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXkslyntL8%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Weiss JM, et al. Endogenous sex hormones and the risk of prostate cancer: a prospective study. Int J Cancer 2008;122(10):2345–50.</BibUnstructured>
            </Citation>
            <Citation ID="CR25_4">
              <CitationNumber>25.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>AW</Initials>
                  <FamilyName>Hsing</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>LW</Initials>
                  <FamilyName>Chu</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>FZ</Initials>
                  <FamilyName>Stanczyk</FamilyName>
                </BibAuthorName>
                <Year>2008</Year>
                <ArticleTitle Language="En">Androgen and prostate cancer: is the hypothesis dead?</ArticleTitle>
                <JournalTitle>Cancer Epidemiol Biomarkers Prev</JournalTitle>
                <VolumeID>17</VolumeID>
                <IssueID>10</IssueID>
                <FirstPage>2525</FirstPage>
                <LastPage>30</LastPage>
                <Occurrence Type="PID">
                  <Handle>18842992</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1158/1055-9965.EPI-08-0448</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXht1egt73F</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Hsing AW, Chu LW, Stanczyk FZ. Androgen and prostate cancer: is the hypothesis dead? Cancer Epidemiol Biomarkers Prev 2008;17(10):2525–30.</BibUnstructured>
            </Citation>
            <Citation ID="CR26_4">
              <CitationNumber>26.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Mulligan</FamilyName>
                </BibAuthorName>
                <Year>2006</Year>
                <ArticleTitle Language="En">Prevalence of hypogonadism in males aged at least 45 years: the HIM study</ArticleTitle>
                <JournalTitle>Int J Clin Pract</JournalTitle>
                <VolumeID>60</VolumeID>
                <IssueID>7</IssueID>
                <FirstPage>762</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>16846397</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1111/j.1742-1241.2006.00992.x</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28XovFyktLc%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Mulligan T, et al. Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int J Clin Pract 2006;60(7):762–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR27_4">
              <CitationNumber>27.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JL</Initials>
                  <FamilyName>Tostain</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>F</Initials>
                  <FamilyName>Blanc</FamilyName>
                </BibAuthorName>
                <Year>2008</Year>
                <ArticleTitle Language="En">Testosterone deficiency: a common, unrecognized syndrome</ArticleTitle>
                <JournalTitle>Nat Clin Pract Urol</JournalTitle>
                <VolumeID>5</VolumeID>
                <IssueID>7</IssueID>
                <FirstPage>388</FirstPage>
                <LastPage>96</LastPage>
                <Occurrence Type="PID">
                  <Handle>18604225</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1038/ncpuro1167</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXotFaktLY%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Tostain JL, Blanc F. Testosterone deficiency: a common, unrecognized syndrome. Nat Clin Pract Urol 2008;5(7):388–96.</BibUnstructured>
            </Citation>
            <Citation ID="CR28_4">
              <CitationNumber>28.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>HB</Initials>
                  <FamilyName>Carter</FamilyName>
                </BibAuthorName>
                <Year>1995</Year>
                <ArticleTitle Language="En">Longitudinal evaluation of serum androgen levels in men with and without prostate cancer</ArticleTitle>
                <JournalTitle>Prostate</JournalTitle>
                <VolumeID>27</VolumeID>
                <IssueID>1</IssueID>
                <FirstPage>25</FirstPage>
                <LastPage>31</LastPage>
                <Occurrence Type="PID">
                  <Handle>7541528</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/pros.2990270106</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2MXnsFKrtLc%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Carter HB, et al. Longitudinal evaluation of serum androgen levels in men with and without prostate cancer. Prostate 1995;27(1):25–31.</BibUnstructured>
            </Citation>
            <Citation ID="CR29_4">
              <CitationNumber>29.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Slater</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RT</Initials>
                  <FamilyName>Oliver</FamilyName>
                </BibAuthorName>
                <Year>2000</Year>
                <ArticleTitle Language="En">Testosterone: its role in development of prostate cancer and potential risk from use as hormone replacement therapy</ArticleTitle>
                <JournalTitle>Drugs Aging</JournalTitle>
                <VolumeID>17</VolumeID>
                <IssueID>6</IssueID>
                <FirstPage>431</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>11200304</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.2165/00002512-200017060-00001</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3MXnvFShtA%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Slater S, Oliver RT. Testosterone: its role in development of prostate cancer and potential risk from use as hormone replacement therapy. Drugs Aging 2000;17(6):431–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR30_4">
              <CitationNumber>30.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>RK</Initials>
                  <FamilyName>Ross</FamilyName>
                </BibAuthorName>
                <Year>1992</Year>
                <ArticleTitle Language="En">5-Alpha-reductase activity and risk of prostate cancer among Japanese and US white and black males</ArticleTitle>
                <JournalTitle>Lancet</JournalTitle>
                <VolumeID>339</VolumeID>
                <IssueID>8798</IssueID>
                <FirstPage>887</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>1348296</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/0140-6736(92)90927-U</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK383ht1Sjsg%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Ross RK, et al. 5-Alpha-reductase activity and risk of prostate cancer among Japanese and US white and black males. Lancet 1992;339(8798):887–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR31_4">
              <CitationNumber>31.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>AH</Initials>
                  <FamilyName>Wu</FamilyName>
                </BibAuthorName>
                <Year>1995</Year>
                <ArticleTitle Language="En">Serum androgens and sex hormone-binding globulins in relation to lifestyle factors in older African-American, white, and Asian men in the United States and Canada</ArticleTitle>
                <JournalTitle>Cancer Epidemiol Biomarkers Prev</JournalTitle>
                <VolumeID>4</VolumeID>
                <IssueID>7</IssueID>
                <FirstPage>735</FirstPage>
                <LastPage>41</LastPage>
                <Occurrence Type="PID">
                  <Handle>8672990</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2MXpslWnt74%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Wu AH, et al. Serum androgens and sex hormone-binding globulins in relation to lifestyle factors in older African-American, white, and Asian men in the United States and Canada. Cancer Epidemiol Biomarkers Prev 1995;4(7):735–41.</BibUnstructured>
            </Citation>
            <Citation ID="CR32_4">
              <CitationNumber>32.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Morgentaler</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CO</Initials>
                  <FamilyName>Bruning</FamilyName>
                  <Suffix>3rd</Suffix>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WC</Initials>
                  <FamilyName>DeWolf</FamilyName>
                </BibAuthorName>
                <Year>1996</Year>
                <ArticleTitle Language="En">Occult prostate cancer in men with low serum testosterone levels</ArticleTitle>
                <JournalTitle>JAMA</JournalTitle>
                <VolumeID>276</VolumeID>
                <IssueID>23</IssueID>
                <FirstPage>1904</FirstPage>
                <LastPage>6</LastPage>
                <Occurrence Type="PID">
                  <Handle>8968017</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1001/jama.1996.03540230054035</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK2s7it1eqtQ%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Morgentaler A, Bruning 3rd CO, DeWolf WC. Occult prostate cancer in men with low serum testosterone levels. JAMA 1996;276(23):1904–6.</BibUnstructured>
            </Citation>
            <Citation ID="CR33_4">
              <CitationNumber>33.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Morgentaler</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>EL</Initials>
                  <FamilyName>Rhoden</FamilyName>
                </BibAuthorName>
                <Year>2006</Year>
                <ArticleTitle Language="En">Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/mL or less</ArticleTitle>
                <JournalTitle>Urology</JournalTitle>
                <VolumeID>68</VolumeID>
                <IssueID>6</IssueID>
                <FirstPage>1263</FirstPage>
                <LastPage>7</LastPage>
                <Occurrence Type="PID">
                  <Handle>17169647</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/j.urology.2006.08.1058</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Morgentaler A, Rhoden EL. Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/mL or less. Urology 2006;68(6):1263–7.</BibUnstructured>
            </Citation>
            <Citation ID="CR34_4">
              <CitationNumber>34.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Yamamoto</FamilyName>
                </BibAuthorName>
                <Year>2007</Year>
                <ArticleTitle Language="En">Preoperative serum testosterone level as an independent predictor of treatment failure following radical prostatectomy</ArticleTitle>
                <JournalTitle>Eur Urol</JournalTitle>
                <VolumeID>52</VolumeID>
                <IssueID>3</IssueID>
                <FirstPage>696</FirstPage>
                <LastPage>701</LastPage>
                <Occurrence Type="PID">
                  <Handle>17412490</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/j.eururo.2007.03.052</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXhtVKgs7zN</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Yamamoto S, et al. Preoperative serum testosterone level as an independent predictor of treatment failure following radical prostatectomy. Eur Urol 2007;52(3):696–701.</BibUnstructured>
            </Citation>
            <Citation ID="CR35_4">
              <CitationNumber>35.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>MA</Initials>
                  <FamilyName>Hoffman</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WC</Initials>
                  <FamilyName>DeWolf</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Morgentaler</FamilyName>
                </BibAuthorName>
                <Year>2000</Year>
                <ArticleTitle Language="En">Is low serum free testosterone a marker for high grade prostate cancer?</ArticleTitle>
                <JournalTitle>J Urol</JournalTitle>
                <VolumeID>163</VolumeID>
                <IssueID>3</IssueID>
                <FirstPage>824</FirstPage>
                <LastPage>7</LastPage>
                <Occurrence Type="PID">
                  <Handle>10687985</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S0022-5347(05)67812-3</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3cXhsVSjuro%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Hoffman MA, DeWolf WC, Morgentaler A. Is low serum free testosterone a marker for high grade prostate cancer? J Urol 2000;163(3):824–7.</BibUnstructured>
            </Citation>
            <Citation ID="CR36_4">
              <CitationNumber>36.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Schatzl</FamilyName>
                </BibAuthorName>
                <Year>2001</Year>
                <ArticleTitle Language="En">High-grade prostate cancer is associated with low serum testosterone levels</ArticleTitle>
                <JournalTitle>Prostate</JournalTitle>
                <VolumeID>47</VolumeID>
                <IssueID>1</IssueID>
                <FirstPage>52</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>11304729</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/pros.1046</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3MXjtVCju74%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Schatzl G, et al. High-grade prostate cancer is associated with low serum testosterone levels. Prostate 2001;47(1):52–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR37_4">
              <CitationNumber>37.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JC</Initials>
                  <FamilyName>Massengill</FamilyName>
                </BibAuthorName>
                <Year>2003</Year>
                <ArticleTitle Language="En">Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy</ArticleTitle>
                <JournalTitle>J Urol</JournalTitle>
                <VolumeID>169</VolumeID>
                <IssueID>5</IssueID>
                <FirstPage>1670</FirstPage>
                <LastPage>5</LastPage>
                <Occurrence Type="PID">
                  <Handle>12686805</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1097/01.ju.0000062674.43964.d0</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Massengill JC, et al. Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy. J Urol 2003;169(5):1670–5.</BibUnstructured>
            </Citation>
            <Citation ID="CR38_4">
              <CitationNumber>38.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Ribeiro</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Ruff</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Falkson</FamilyName>
                </BibAuthorName>
                <Year>1997</Year>
                <ArticleTitle Language="En">Low serum testosterone and a younger age predict for a poor outcome in metastatic prostate cancer</ArticleTitle>
                <JournalTitle>Am J Clin Oncol</JournalTitle>
                <VolumeID>20</VolumeID>
                <IssueID>6</IssueID>
                <FirstPage>605</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>9391550</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1097/00000421-199712000-00015</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK1c%2FltlSgug%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Ribeiro M, Ruff P, Falkson G. Low serum testosterone and a younger age predict for a poor outcome in metastatic prostate cancer. Am J Clin Oncol 1997;20(6):605–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR39_4">
              <CitationNumber>39.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Sih</FamilyName>
                </BibAuthorName>
                <Year>1997</Year>
                <ArticleTitle Language="En">Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial</ArticleTitle>
                <JournalTitle>J Clin Endocrinol Metab</JournalTitle>
                <VolumeID>82</VolumeID>
                <IssueID>6</IssueID>
                <FirstPage>1661</FirstPage>
                <LastPage>7</LastPage>
                <Occurrence Type="PID">
                  <Handle>9177359</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1210/jc.82.6.1661</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2sXjs1WrsLo%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Sih R, et al. Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial. J Clin Endocrinol Metab 1997;82(6):1661–7.</BibUnstructured>
            </Citation>
            <Citation ID="CR40_4">
              <CitationNumber>40.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>DA</Initials>
                  <FamilyName>Svetec</FamilyName>
                </BibAuthorName>
                <Year>1997</Year>
                <ArticleTitle Language="En">The effect of parenteral testosterone replacement on prostate specific antigen in hypogonadal men with erectile dysfunction</ArticleTitle>
                <JournalTitle>J Urol</JournalTitle>
                <VolumeID>158</VolumeID>
                <IssueID>5</IssueID>
                <FirstPage>1775</FirstPage>
                <LastPage>7</LastPage>
                <Occurrence Type="PID">
                  <Handle>9334599</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S0022-5347(01)64126-0</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1cXmsVOrtLc%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Svetec DA, et al. The effect of parenteral testosterone replacement on prostate specific antigen in hypogonadal men with erectile dysfunction. J Urol 1997;158(5):1775–7.</BibUnstructured>
            </Citation>
            <Citation ID="CR41_4">
              <CitationNumber>41.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>AM</Initials>
                  <FamilyName>Kenny</FamilyName>
                </BibAuthorName>
                <Year>2001</Year>
                <ArticleTitle Language="En">Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels</ArticleTitle>
                <JournalTitle>J Gerontol A Biol Sci Med Sci</JournalTitle>
                <VolumeID>56</VolumeID>
                <IssueID>5</IssueID>
                <FirstPage>M266</FirstPage>
                <LastPage>72</LastPage>
                <Occurrence Type="PID">
                  <Handle>11320105</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1093/gerona/56.5.M266</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DC%2BD3M3ntFygsQ%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Kenny AM, et al. Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels. J Gerontol A Biol Sci Med Sci 2001;56(5):M266–72.</BibUnstructured>
            </Citation>
            <Citation ID="CR42_4">
              <CitationNumber>42.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>PJ</Initials>
                  <FamilyName>Snyder</FamilyName>
                </BibAuthorName>
                <Year>2000</Year>
                <ArticleTitle Language="En">Effects of testosterone replacement in hypogonadal men</ArticleTitle>
                <JournalTitle>J Clin Endocrinol Metab</JournalTitle>
                <VolumeID>85</VolumeID>
                <IssueID>8</IssueID>
                <FirstPage>2670</FirstPage>
                <LastPage>7</LastPage>
                <Occurrence Type="PID">
                  <Handle>10946864</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1210/jc.85.8.2670</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3cXnslaiu7w%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Snyder PJ, et al. Effects of testosterone replacement in hypogonadal men. J Clin Endocrinol Metab 2000;85(8):2670–7.</BibUnstructured>
            </Citation>
            <Citation ID="CR43_4">
              <CitationNumber>43.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>EL</Initials>
                  <FamilyName>Rhoden</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Morgentaler</FamilyName>
                </BibAuthorName>
                <Year>2003</Year>
                <ArticleTitle Language="En">Testosterone replacement therapy in hypogonadal men at high risk for prostate cancer: results of 1 year of treatment in men with prostatic intraepithelial neoplasia</ArticleTitle>
                <JournalTitle>J Urol</JournalTitle>
                <VolumeID>170</VolumeID>
                <IssueID>6 Pt 1</IssueID>
                <FirstPage>2348</FirstPage>
                <LastPage>51</LastPage>
                <Occurrence Type="PID">
                  <Handle>14634413</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1097/01.ju.0000091104.71869.8e</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3sXpvFSksLc%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Rhoden EL, Morgentaler A. Testosterone replacement therapy in hypogonadal men at high risk for prostate cancer: results of 1 year of treatment in men with prostatic intraepithelial neoplasia. J Urol 2003;170(6 Pt 1):2348–51.</BibUnstructured>
            </Citation>
            <Citation ID="CR44_4">
              <CitationNumber>44.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>EL</Initials>
                  <FamilyName>Rhoden</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Morgentaler</FamilyName>
                </BibAuthorName>
                <Year>2004</Year>
                <ArticleTitle Language="En">Risks of testosterone-replacement therapy and recommendations for monitoring</ArticleTitle>
                <JournalTitle>N Engl J Med</JournalTitle>
                <VolumeID>350</VolumeID>
                <IssueID>5</IssueID>
                <FirstPage>482</FirstPage>
                <LastPage>92</LastPage>
                <Occurrence Type="PID">
                  <Handle>14749457</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1056/NEJMra022251</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXos1Wjsw%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Rhoden EL, Morgentaler A. Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med 2004;350(5):482–92.</BibUnstructured>
            </Citation>
            <Citation ID="CR45_4">
              <CitationNumber>45.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Makinen</FamilyName>
                </BibAuthorName>
                <Year>2004</Year>
                <ArticleTitle Language="En">Second round results of the Finnish population-based prostate cancer screening trial</ArticleTitle>
                <JournalTitle>Clin Cancer Res</JournalTitle>
                <VolumeID>10</VolumeID>
                <IssueID>7</IssueID>
                <FirstPage>2231</FirstPage>
                <LastPage>6</LastPage>
                <Occurrence Type="PID">
                  <Handle>15073097</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1158/1078-0432.CCR-03-0338</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Makinen T, et al. Second round results of the Finnish population-based prostate cancer screening trial. Clin Cancer Res 2004;10(7):2231–6.</BibUnstructured>
            </Citation>
            <Citation ID="CR46_4">
              <CitationNumber>46.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>ED</Initials>
                  <FamilyName>Grober</FamilyName>
                </BibAuthorName>
                <Year>2008</Year>
                <ArticleTitle Language="En">Correlation between simultaneous PSA and serum testosterone concentrations among eugonadal, untreated hypogonadal and hypogonadal men receiving testosterone replacement therapy</ArticleTitle>
                <JournalTitle>Int J Impot Res</JournalTitle>
                <VolumeID>20</VolumeID>
                <IssueID>6</IssueID>
                <FirstPage>561</FirstPage>
                <LastPage>5</LastPage>
                <Occurrence Type="PID">
                  <Handle>18843272</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1038/ijir.2008.40</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXhtlCksrrJ</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Grober ED, et al. Correlation between simultaneous PSA and serum testosterone concentrations among eugonadal, untreated hypogonadal and hypogonadal men receiving testosterone replacement therapy. Int J Impot Res 2008;20(6):561–5.</BibUnstructured>
            </Citation>
            <Citation ID="CR47_4">
              <CitationNumber>47.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>LS</Initials>
                  <FamilyName>Marks</FamilyName>
                </BibAuthorName>
                <Year>2006</Year>
                <ArticleTitle Language="En">Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial</ArticleTitle>
                <JournalTitle>JAMA</JournalTitle>
                <VolumeID>296</VolumeID>
                <IssueID>19</IssueID>
                <FirstPage>2351</FirstPage>
                <LastPage>61</LastPage>
                <Occurrence Type="PID">
                  <Handle>17105798</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1001/jama.296.19.2351</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28Xht1ansb%2FM</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Marks LS, et al. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA 2006;296(19):2351–61.</BibUnstructured>
            </Citation>
            <Citation ID="CR48_4">
              <CitationNumber>48.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JM</Initials>
                  <FamilyName>Kaufman</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RJ</Initials>
                  <FamilyName>Graydon</FamilyName>
                </BibAuthorName>
                <Year>2004</Year>
                <ArticleTitle Language="En">Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men</ArticleTitle>
                <JournalTitle>J Urol</JournalTitle>
                <VolumeID>172</VolumeID>
                <IssueID>3</IssueID>
                <FirstPage>920</FirstPage>
                <LastPage>2</LastPage>
                <Occurrence Type="PID">
                  <Handle>15310998</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1097/01.ju.0000136269.10161.32</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXms1Grsrg%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Kaufman JM, Graydon RJ. Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men. J Urol 2004;172(3):920–2.</BibUnstructured>
            </Citation>
            <Citation ID="CR49_4">
              <CitationNumber>49.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>PK</Initials>
                  <FamilyName>Agarwal</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MG</Initials>
                  <FamilyName>Oefelein</FamilyName>
                </BibAuthorName>
                <Year>2005</Year>
                <ArticleTitle Language="En">Testosterone replacement therapy after primary treatment for prostate cancer</ArticleTitle>
                <JournalTitle>J Urol</JournalTitle>
                <VolumeID>173</VolumeID>
                <IssueID>2</IssueID>
                <FirstPage>533</FirstPage>
                <LastPage>6</LastPage>
                <Occurrence Type="PID">
                  <Handle>15643240</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1097/01.ju.0000143942.55896.64</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXitl2qtg%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Agarwal PK, Oefelein MG. Testosterone replacement therapy after primary treatment for prostate cancer. J Urol 2005;173(2):533–6.</BibUnstructured>
            </Citation>
            <Citation ID="CR50_4">
              <CitationNumber>50.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>MF</Initials>
                  <FamilyName>Sarosdy</FamilyName>
                </BibAuthorName>
                <Year>2007</Year>
                <ArticleTitle Language="En">Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy</ArticleTitle>
                <JournalTitle>Cancer</JournalTitle>
                <VolumeID>109</VolumeID>
                <IssueID>3</IssueID>
                <FirstPage>536</FirstPage>
                <LastPage>41</LastPage>
                <Occurrence Type="PID">
                  <Handle>17183557</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/cncr.22438</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXitV2itrk%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Sarosdy MF. Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy. Cancer 2007;109(3):536–41.</BibUnstructured>
            </Citation>
          </Bibliography>
        </ChapterBackmatter>
      </Chapter>
    </Part>
  </Book>
</Publisher>
